Characterization of Angelman Syndrome

Status Completed

Clinical Trial Summary

Angelman Syndrome (AS) is a developmental disorder that is caused by a deficiency of a maternally transmitted gene. It is inherited at birth, and affects movement, speech, and social demeanor. This study will gain a better understanding of the disease progression and clinical features of AS by observing children with AS over an extended period of time.

Clinical Trial Description

AS is a developmental disorder that affects movement, speech, and social demeanor. The disorder is caused by a deficiency of a maternally transmitted gene and is inherited at birth. Children with AS, however, are often not diagnosed until they are between 3 and 7 years old. Symptoms of AS may include, but are not limited to, functionally severe developmental delay; speech impairments; movement or balance problems; and behavioral uniqueness, including any combination of frequent laughter or smiling, apparent happy demeanor, easily excitable personality, hand flapping movements, and short attention span. There are four molecular variations of AS, but past clinical studies have been inconsistent in highlighting the phenotypic differences between them. This study will gain a better understanding of the disease progression and clinical features of AS by observing children with AS over a period of 5 to 10 years. The study will also attempt to establish genotype-phenotype correlations, which might aid in future clinical care of AS patients. Participation in this observational study will be limited to current or future patients at one of the five study sites. A clinical evaluation will be performed at baseline, including a general patient history, physical and neurological examinations, a nutritional assessment, neuro-imaging, electroencephalography, laboratory testing, and neurodevelopmental testing. A blood sample or mucosal sample will also be taken at baseline to acquire DNA for potential genetic testing. All assessments except the neuro-imaging, electroencephalography, and blood sampling will be repeated at yearly study visits for as long as funding can be secured. In addition, participants will be photographed and perhaps videotaped on a yearly basis in order to document clinical phenotypes and any neurologic abnormalities. Participants may be followed-up for a total of 10 years. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00296764
Study type	Observational
Source	Boston Children's Hospital
Contact
Status	Completed
Phase
Start date	February 2006
Completion date	August 2014

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05293184` - The Global Angelman Syndrome Registry
Completed	`NCT00004351` - Study of Phenotype and Genotype Correlations in Patients With Contiguous Gene Deletion Syndromes	N/A
Enrolling by invitation	`NCT06139172` - Promoting Prosocial Behavior in Syndromic Intellectual and Developmental Disabilities	N/A
Enrolling by invitation	`NCT03655223` - Early Check: Expanded Screening in Newborns
Recruiting	`NCT06229769` - Natural History Study for Patients With Angelman Syndrome
Enrolling by invitation	`NCT03836300` - Parent-Infant Inter(X)Action Intervention (PIXI)	N/A
Completed	`NCT03235037` - Clinical Trial of Levodopa/Carbidopa ( Sinemet) Therapy in Angel Man Syndrome	N/A
Recruiting	`NCT05100810` - Angelman Syndrome Natural History Study-FAST UK
Completed	`NCT03644693` - Nutritional Formulation for Angelman Syndrome	N/A
Completed	`NCT03358823` - Study on the Brain Network of Angelman Syndrome
Recruiting	`NCT06337383` - Study of the Prevalence of Autistic Traits in Angelman Syndrome
Recruiting	`NCT05945576` - IDMet (RaDiCo Cohort) (RaDiCo-IDMet)
Completed	`NCT02670694` - Sleep Abnormalities in Rare Genetic Disorders: AS, RTT, and PW	N/A
Recruiting	`NCT04768803` - Ghrelin in Patients With a Rare Disease Associated With Intellectual Disability, and Hyperphagia, and/or Overweight, and/or Obesity
Recruiting	`NCT05630066` - Study to Investigate the Pharmacokinetics and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype.	Phase 2
Completed	`NCT00348933` - Dietary Supplements for the Treatment of Angelman Syndrome	N/A
Recruiting	`NCT05011851` - An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman Syndrome	Phase 2
Terminated	`NCT03882918` - An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals With Angelman Syndrome	Phase 3
Completed	`NCT02996305` - A Study in Adults and Adolescents With Angelman Syndrome (STARS)	Phase 2
Completed	`NCT02056665` - Study to Evaluate the Efficacy and Safety of Minocycline in Angelman Syndrome	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.